Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Thyroid Disorders
How long should T3 be continued in hypothyroid patients who received no symptomatic benefit after starting T3/T4 combination therapy?
Answer from: at Community Practice
I stop at next visit and increase T4 replacement accordingly.
Sign in or Register to read more
Answer from: at Community Practice
If no side effects, I ask them to continue it until 6-12 weeks before fully stopping it. Sometimes, they notice they were better with it after they stop it. But most just stop it.
Sign in or Register to read more
19606
20297
Related Questions
Do SSRIs affect the absorption of Levothyroxine therapy when taken concomitantly?
Should all thyroid cancer patients have thyroglobulin levels measured pre-operatively?
How often should TSH levels be monitored in patients with a history of Graves' disease who are in remission with negative TSI/TBII antibodies and off medical therapy?
What workup do you recommend for patients requiring higher-than-expected levothyroxine doses for their weight?
What specific features in a patient with euthyroid MNG increase their risk of developing functional autonomy and overt hyperthyroidism?
What are the treatment options for refractory dysthyroid optic neuropathy in a patient with extensive gastrointestinal history including gastric ulcers and colitis?
What is your approach to determining recurrent versus RAI-refractory differentiated thyroid cancer in patients presenting with metastatic disease several years after surgery?
How do you approach treatment of depression in Graves' Disease?
What is the utility of checking reverse T3 in clinical practice?
What strategies do you employ for adjusting the dosage of levothyroxine in hypothyroid patients who experience significant weight loss or are initiated on GLP-1 receptor agonists?